• LAST PRICE
    3.4200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.3000/ 2
  • Ask / Lots
    3.9100/ 3
  • Open / Previous Close
    0.0000 / 3.4200
  • Day Range
    ---
  • 52 Week Range
    Low 2.7650
    High 4.6000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.49
TimeVolumeAVIR
09:32 ET219683.53
09:34 ET69933.52
09:36 ET3003.53
09:38 ET6243.51
09:39 ET1003.51
09:41 ET2003.495
09:43 ET5503.49
09:45 ET9113.49
09:48 ET6383.49
09:50 ET9223.49
09:52 ET2003.49
09:54 ET12493.49
09:56 ET1313.49
09:59 ET10033.48
10:01 ET22003.485
10:06 ET44003.47
10:08 ET4003.475
10:15 ET34173.465
10:17 ET30283.47
10:21 ET2003.475
10:24 ET1003.475
10:26 ET133763.505
10:32 ET1003.51
10:33 ET24713.515
10:35 ET5003.515
10:37 ET4003.52
10:39 ET5003.52
10:42 ET30073.52
10:46 ET1003.515
10:48 ET1003.52
10:50 ET3583.515
11:02 ET2003.51
11:04 ET9513.515
11:06 ET1003.515
11:08 ET5403.52
11:09 ET4533.52
11:11 ET14153.51
11:13 ET9403.52
11:15 ET5003.52
11:18 ET2003.52
11:20 ET6003.52
11:22 ET4403.515
11:24 ET7473.52
11:26 ET4003.52
11:27 ET6293.52
11:31 ET100073.475
11:33 ET3683.475
11:36 ET45003.4938
11:40 ET3003.5
11:44 ET5613.51
11:47 ET4133.505
11:49 ET3003.505
11:51 ET6003.5
11:54 ET8003.505
11:56 ET4003.51
11:58 ET7003.505
12:00 ET6003.505
12:02 ET5003.505
12:03 ET4003.5099
12:05 ET7003.505
12:07 ET9143.505
12:09 ET15173.49
12:12 ET4003.48
12:14 ET7003.485
12:16 ET4003.48
12:18 ET17743.495
12:20 ET8003.495
12:25 ET2003.495
12:30 ET2003.495
12:32 ET2003.495
12:36 ET1003.495
12:38 ET3003.495
12:39 ET2003.49
12:41 ET5003.49
12:45 ET3943.48
12:50 ET1003.48
12:52 ET1003.47
12:56 ET2503.475
12:59 ET1003.47
01:01 ET1003.475
01:03 ET2003.47
01:06 ET1003.475
01:08 ET3003.47
01:10 ET3003.475
01:14 ET1003.47
01:15 ET1003.47
01:17 ET1003.47
01:19 ET1003.475
01:21 ET2233.475
01:24 ET1003.47
01:28 ET6003.47
01:30 ET10003.465
01:33 ET1003.465
01:35 ET1003.46
01:37 ET3263.46
01:42 ET48943.475
01:44 ET1003.475
01:48 ET1003.47
01:50 ET10523.475
01:53 ET2263.475
01:55 ET1003.47
01:57 ET7403.475
02:02 ET1003.475
02:06 ET1003.475
02:08 ET2003.475
02:11 ET2003.47
02:13 ET13263.475
02:15 ET11003.475
02:18 ET6003.475
02:20 ET2003.475
02:24 ET9003.475
02:26 ET1003.475
02:27 ET2003.475
02:31 ET3003.475
02:33 ET15033.485
02:36 ET1003.485
02:38 ET5043.485
02:42 ET1003.485
02:44 ET2003.485
02:45 ET6003.485
02:47 ET2003.485
02:49 ET4003.485
02:51 ET8003.485
02:58 ET1003.485
03:00 ET5733.485
03:02 ET2003.485
03:03 ET24173.475
03:07 ET9943.465
03:12 ET1003.465
03:14 ET67113.45
03:16 ET25243.435
03:21 ET8003.435
03:23 ET1003.435
03:25 ET16973.43
03:30 ET2003.425
03:32 ET18693.425
03:34 ET41523.425
03:36 ET21933.425
03:38 ET92753.41
03:39 ET31383.405
03:41 ET44803.405
03:43 ET2143.4
03:45 ET9103.41
03:48 ET16003.43
03:50 ET3003.42
03:52 ET19583.425
03:54 ET4003.425
03:56 ET3003.425
03:57 ET14583.43
03:59 ET150383.42
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAVIR
Atea Pharmaceuticals Inc
288.0M
-1.7x
---
United StatesOPT
Opthea Ltd
289.7M
-0.8x
---
United StatesBDTX
Black Diamond Therapeutics Inc
280.1M
-2.9x
---
United StatesANRO
Alto Neuroscience Inc
297.1M
-5.8x
---
United StatesINZY
Inozyme Pharma Inc
272.2M
-3.2x
---
United StatesIMMP
Immutep Ltd
395.0M
0.0x
---
As of 2024-06-21

Company Information

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Contact Information

Headquarters
225 Franklin Street, Suite 2100BOSTON, MA, United States 02110
Phone
857-204-8109
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Founder
Jean-Pierre Sommadossi
Chief Financial Officer, Executive Vice President - Legal , Secretary
Andrea Corcoran
Executive Vice President, Chief Accounting Officer
Wayne Foster
Chief Development Officer
Janet Hammond
Chief Medical Officer
Maria Horga

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$288.0M
Revenue (TTM)
$0.00
Shares Outstanding
84.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.18
EPS
$-1.96
Book Value
$6.65
P/E Ratio
-1.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.